| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Clobetasol propionate 500 microgram/g cutaneous gel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely clobetasol propionate 500 microgram/1 milliliter conventional release cutaneous solution (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Acetic acid 20 mg/mL and hydrocortisone 10 mg/mL ear solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Acetic acid, glacial + hydrocortisone 2%vv/1%wv solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Benzoyl peroxide + hydrocortisone 50mg/5mg lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone acetate + betamethasone sodium phosphate 3mg/3mg per mL injection suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone acetate + betamethasone sodium phospha 3mg/ns soluspan |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone dipropionate + clotrimazole 0.64mg/10mg cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone dipropionate + clotrimazole ns/10mg lotion (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chloroxylenol + hydrocortisone + pramoxine hydrochloride 1mg/10mg/10mg drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clioquinol + hydrocortisone + pramoxine hydrochloride 3%ww/1%ww/0.5%ww |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clioquinol + hydrocortisone 3%ww/0.5%ww cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clioquinol + hydrocortisone 3%ww/0.5%ww lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clioquinol + hydrocortisone 30mg/10mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Colistin sulfate + hydrocortisone acetate + neomycin sulfate 0ns/10mg/0ns solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone + neomycin sulfate + polymyxin b sulfate 0.1%wv/ns/10000unt ointment (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone + neomycin sulfate + polymyxin b sulphate 0.1%wv/ns/10000unt suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone + neomycin sulphate 1mg/3.5mg ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone + tobramycin 0.1%wv/0.3%wv suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone + tobramycin 1mg/3mg ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone phosphate + dexamethasone sodium phospha 1mg/0ns solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone sodium phospha + lidocaine hydrochloride 0ns/10mg (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone sodium phospha + neomycin sulphate 0ns/0ns solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone sodium phosphate + neomycin sulfate 1mg/3.5gm solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fluorometholone + sulfacetamide sodium 0.1%wv/10%wv suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Gentamicin sulfate + prednisolone acetate 0ns/0.6%ww ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Gentamicin sulfate + prednisolone acetate 0ns/10%vv suspension (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hexachlorophene + hydrocortisone + menthol 5mg/5mg/1.25mg topical cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone + neomycin sulfate + polymyxin b sulphate 10mg/5mg/1.6mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone + neomycin sulfate + polymyxin b sulfate 10mg/5mg/10000unt sol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone+neomycin sulfate+polymyxin b sulphate 10mg/5ns/10000unt suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone + neomycin sulfate + polymyxin b sulphate 10mg/7.5mg/10000unt suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone + neomycin sulfate + polymyxin b sulphate 10mg/7.5mg/1000unt solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone + polymyxin b 5mg/10000unt drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate + neomycin sulfate + polymyxin b sulfate 5mg/3.5mg/10000unit cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate + pramoxine hydrochloride 1%wv/1%wv lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate + pramoxine hydrochloride 1%ww/1%ww aerosol |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate 10 mg/mL and pramocaine hydrochloride 10 mg/mL cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate 25 mg/mL and pramocaine hydrochloride 10 mg/mL cutaneous cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate + pramoxine hydrochloride 2.5%ww/1%ww lotion |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate + pramoxine hydrochloride 2.5%ww/1%ww ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Neomycin sulfate + polymyxin b sulfate + prednisolone acetate 0.35%/10000unt/0.5%wv suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nystatin + triamcinolone acetonide 100000unt/1mg cream |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nystatin + triamcinolone acetonide 100000unt/1mg ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Nystatin + triamcinolone acetonide 10000unt/1mg ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone acetate + sulfacetamide sodium 0.2%wv/10%wv suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely prednisolone acetate 2 milligram/1 gram and sulfacetamide sodium 100 milligram/1 gram conventional release eye ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone acetate + sulfacetamide sodium 0.25%wv/10%wv suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone acetate 2.5 mg/g and sulfacetamide sodium 100 mg/g eye ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone acetate + sulfacetamide sodium 5mg/100mg ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone acetate + sulfacetamide sodium 5mg/100mg suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone sodium phosphate + sulfacetamide sodium 2.5mg/100mg solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone+calcipotriol (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone sodium phosphate 24mg injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone sodium phosphate 4mg injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Dexamethasone sodium phospha 10mg injection solution vial (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely betamethasone (as betamethasone valerate) 1 milligram/1 gram conventional release cutaneous ointment (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clioquinol+flumethasone pivalate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing benzoyl peroxide and hydrocortisone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ascorbic acid- and clioquinol-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing neomycin sulfate and polymyxin B sulfate and prednisolone acetate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Colistin sulfate + hydrocortisone acetate + neomycin sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Chloroxylenol + hydrocortisone + pramoxine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing hydrocortisone and neomycin sulfate and polymyxin B sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Ciprofloxacin 0.2% + hydrocortisone 1% otic solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate+neomycin sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Gentamicin sulfate + prednisolone acetate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone dipropionate + clotrimazole |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| médicament contenant dexaméthasone et néomycine et polymyxine B |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing dexamethasone sodium phosphate and neomycin sulfate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Diiodohydroxyquinoline- and hydrocortisone-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Clioquinol + hydrocortisone + pramoxine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Methylprednisolone sodium su 125mg/vial powder for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate 50mg/mL injection suspension 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone sodium succinate 1000mg/vial powder for injection 8mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone sodium phospha 3mg/mL injection solution 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone sodium phosphate 20mg/mL injection solution 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone acetate 50mg/mL injection suspension 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone sodium succin 500mg/vial powder for injection 4mL vial (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Betamethasone sodium phosphate 4mg/mL injection solution 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone sodium phosphat 20mg/mL injection solution 10mL vial (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone hexacetonide 20mg/mL injection suspension 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone acetate 50mg/mL injection suspension 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing precisely dexamethasone isonicotinate 20 microgram and tramazoline hydrochloride 120 microgram/1 actuation conventional release nasal spray (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone acetate + sulfacetamide sodium 0.5%ww/10%ww ointment |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone 1% / Pramocaine 1% foam enema (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone hexacetonide 5mg/mL injection suspension 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone sodium phosphat 20mg/mL injection solution 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Cortisone acetate 50mg/mL injection suspension 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Tridesilon |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone acetate 50mg/mL injection suspension 30mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone sodium succinate 250mg/vial powder for injection 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Product containing prednisolone sodium phosphate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone sodium phosphate 50mg/mL injection solution 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Hydrocortisone sodium succinate 100mg/vial powder for injection 2mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Prednisolone 20mg/100mL enema |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Budesonide refill 100dose |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Budesonide refill 200dose |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone 40mg/1mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
| Triamcinolone 80mg/2mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Adrenal hormone agent |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.4-SNAPSHOT
|
FHIR Version n/a
User: [n/a]